Natalia A. NinoAssociateK&L Gates LLPWebsitewww.klgates.comOrganization ProfileFull ProfileConnectEmail919-466-1125 Professional Biography Natalia Nino is an associate in the firm’s Research Triangle Park office. She is a member of the Health Care and FDA practice group. More Legal and Business Bylines From Natalia A. Nino The False Claims Act and Health Care: 2023 Recoveries and 2024 Outlook - (Posted On Tuesday, June 18, 2024) US Department of Justice Announces US $2.68 billion in Fiscal Year 2023 False Claims Act Recoveries - (Posted On Thursday, February 29, 2024) 7 To 2 - The Us Supreme Court Confirms That Federal Nursing Home Reform Act Creates Patient Enforceable Rights - (Posted On Thursday, June 22, 2023) Supreme Court Issues Decision Regarding False Claims Act's Scienter Element - (Posted On Thursday, June 08, 2023) Current Legal Analysis USCIS Announces Initial FY 2026 H-1B Cap Selection: What Employers Need to Do Next by: Jessica K. Lang SEC Provides Further Clarity in Rule 506(c) Offerings by: Daniel I. DeWolf , Samuel Asher Effron FedRAMP 20x – Major Overhaul Announced to Streamline the Security Authorization Process for Government Cloud Offerings by: Townsend L. Bourne , Daniel J. Alvarado USDA Will Fund 543 Projects in 29 States Through Higher Blends Infrastructure Incentive Program by: Lynn L. Bergeson , Carla N. Hutton Immigration Enforcement and Healthcare Facilities: Key Considerations for Providers by: Lotan Barbaresso , Amy J. Dilcher The Third Time’s A Charm: Colorado Adds Nuclear Energy as a Clean Energy Resource by: Thomas J. Dougherty SEC Policy Shift and Recent Corp Fin Updates – Part 1 by: Julie F. Rizzo , Linsey N. Taulbee Corporate Transparency Act Update: Drastic Reduction in Scope of BOI Reporting in March 21, 2025 FinCEN Guidance by: Jonathan F.X. O’Brien USPTO Implements Bifurcated Review Process for Patent Petitions Under New Policy by: Preston H. Heard , Kyle W. Kellar Trump Administration Efforts to Eliminate Cartels Pose Heightened Risk for Financial Institutions by: Seth D. DuCharme GLP-1 Receptor Agonists: Drug Litigation Overview and Trends by: Liane M. Peterson Supreme Court Declines Review of “Relational Analysis” for Determining Administrative Exemption by: Michael Reed Kentucky Legislature Ends Judicial Deference To State Agencies by: Stephen P. Kranz , Michael J. Hilkin VHA and DLA Enter Into Another Interagency Agreement: Déjà Vu All Over Again? by: Merle M. DeLancey Jr. When Is Conduct ‘Primarily and Substantially’ in Massachusetts Under Chapter 93A? by: David G. Thomas , Angela C. Bunnell Upcoming Events Apr 30 2025 Workplace Horizons 2025 Apr 3 2025 Defense Counsel: Obligations to Insured Clients and Insurers Apr 3 2025 Defense Counsel: Obligations to Insured Clients and Insurers Apr 7 2025 Understanding the Basics of a Class Action Print
